REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
07/20/2026
Back to search
Official data from USPTO
NANOPRIMER
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
32
Latest update
07/20/2026
Trademark type
Combined
Nice classes
5, 42, 44
Filing date
06/24/2020
Registration date
07/20/2021
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
07/20/2021
Last transaction
07/20/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
5
Owner type
84
Owner location
FR
Examiner
SAITO, KIM
Law office
N60
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of the following: the stylized wording "NANOPRIMER" in white against a blue background.
Holders and representatives
Holders
NANOBIOTIX
Curadigm
Representatives
Michele S. Katz Advitam IP, LLC
Technical classification
Nice Classes
Class 5Class 42Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Products for medical use especially for metabolic pathways to prevent and treat acid-base imbalancemetabolic brain diseasesdisorders of calcium metabolismDNA repair-deficiency disordersglucose metabolism disordershyperlactatemiairon metabolism disorderslipid metabolism disordersmalabsorption syndromesmetabolic syndrome Xinborn error of metabolismmitochondrial diseasesphosphorus metabolism disordersporphyriasproteostasis deficienciesmetabolic skin diseaseswasting syndrome and water-electrolyte imbalance; products for medical use especially for the diagnosis and treatment of tumors; preparations for medical use especially for modifying the bioavailability of therapeutic agents; preparations for medical use especially for modifying liver functions to prevent and treat alcohol-related liver diseasenon-alcoholic fatty liver diseasehepatitishaemochromatosisprimary biliary cirrhosis and liver cancer; preparations for medical use for modifying the functions of the reticuloendothelial system to decrease reticuloendothelial system ability to trap and metabolize therapeutic agents such as nanomedicinesmonoclonal antibodiesantibody-drug conjugatessmall moleculesto prevent and treat Gaucher's diseasemastocytosishistiocytosis; preparations based on nanomaterials for the delivery of therapeutic agents combined with nucleic acidsmall moleculesproteins and peptides; nanoparticles for medical use to prevent and treat central nervous system diseasescancermetabolic diseasesinfectionimmunologic diseaseshematologic diseaserare diseasesorgan transplant rejection; chemical reagents for medical use; bacteriological preparations for medical use; biological preparations for medical use to prevent and treat central nervous system diseasescancermetabolic diseasesinfectionimmunologic diseaseshematologic diseaserare diseasesorgan transplant rejection; enzymes for medical use; enzyme preparations for medical use; diagnostic products for medical use to prevent and treat central nervous system diseasescancermetabolic diseasesinfectionimmunologic diseaseshematologic diseaserare diseasesorgan transplant rejection; drugs for medical use to prevent and treat central nervous system diseasescancermetabolic diseasesinfectionimmunologic diseaseshematologic diseaserare diseasesorgan transplant rejection; medicines for human to prevent and treat central nervous system diseasescancermetabolic diseasesinfectionimmunologic diseaseshematologic diseaserare diseasesorgan transplant rejection; tonics for medical use to prevent and treat central nervous system diseasescancermetabolic diseasesinfectionimmunologic diseaseshematologic diseaserare diseasesorgan transplant rejection; antibiotics; antiseptics; chemico-pharmaceutical preparations for the treatment of central nervous system diseasescancermetabolic diseasesinfectionimmunologic diseaseshematologic diseaserare diseasesorgan transplant rejection; pharmaceutical preparations for the treatment of central nervous system diseasescancermetabolic diseasesinfectionimmunologic diseaseshematologic diseaserare diseasesorgan transplant rejection; dietetic substances preparations adapted for medical use; remedies for human medicine for the treatment of central nervous system diseasescancermetabolic diseasesinfectionimmunologic diseaseshematologic diseaserare diseasesorgan transplant rejection
Class 42
Scientific and technological services as well asresearch and design services particularly in the field of nanomedicine which is nanotechnology applied to medicine; biological research; research in bacteriology; conducting early evaluations in the field of new pharmaceuticals; design and development of new products for third parties; conducting clinical trials for others in the field of new pharmaceuticals; research services in the field of new pharmaceuticals; chemical analysis; chemical research; chemical engineering; chemical research and analysis services in the field of physico-chemical characterization and concept design; engineering worksurveying; research and development of new products for third parties; technical research in the field of new pharmaceuticals; radiobiology research; research in nanoscience and nanotechnologyespecially applied to medicine
Class 44
Healthcare especially in the field of nanomedicine; medical services especially in the field of nanomedicine; hospital services; medical assistance; physiotherapy
Publications
History of USPTO decisions and trademark events.
32 publications found
CHLD
CHANGE OF OWNER RECEIVED FROM IB
12/27/2024
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
12/13/2021
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
12/04/2021
FICS
FINAL DISPOSITION NOTICE SENT TO IB
11/17/2021
FIMP
FINAL DISPOSITION PROCESSED
11/17/2021
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
10/20/2021
R.PR
REGISTERED-PRINCIPAL REGISTER
07/20/2021
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
05/04/2021
PUBO
PUBLISHED FOR OPPOSITION
05/04/2021
GPNX
NOTIFICATION PROCESSED BY IB
05/02/2021
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
04/14/2021
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
04/14/2021
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
04/14/2021
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
03/26/2021
XAEC
EXAMINER'S AMENDMENT ENTERED
03/26/2021
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
03/26/2021
GNEA
EXAMINERS AMENDMENT E-MAILED
03/26/2021
CNEA
EXAMINERS AMENDMENT -WRITTEN
03/26/2021
ZZZX
PREVIOUS ALLOWANCE COUNT WITHDRAWN
03/26/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
01/19/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
01/18/2021
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
01/18/2021
RFNT
REFUSAL PROCESSED BY IB
11/29/2020
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
11/06/2020
RFRR
REFUSAL PROCESSED BY MPU
11/05/2020
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
10/18/2020
CNRT
NON-FINAL ACTION WRITTEN
10/17/2020
DOCK
ASSIGNED TO EXAMINER
09/27/2020
MAFR
APPLICATION FILING RECEIPT MAILED
08/18/2020
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
08/14/2020
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
08/13/2020
Continuous trademark protection
Get notified about every new filing that threatens NANOPRIMER or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.